May 14 (Reuters) - AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to ...

AstraZeneca PLC AZN on Thursday said interim results from the Phase 3 VOLGA trial showed that perioperative treatment with ...

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Building on our strong growth in the first half of the year and continued underlying demand for our medicines we are upgrading our FY 2024 ...

AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set ...

Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 ...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, today announces a licensing agreement with AstraZeneca, a ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

Costco, Coca-Cola and AstraZeneca lead Zacks' top stock reports as strong earnings, growth drivers and pipeline momentum lift ...

A drug developed by AstraZeneca and Daiichi Sankyo to treat breast cancer has been approved by the Food and Drug Administration. Enhertu was approved for two new breast cancer indications for use ...

Agentic AI company Owkin said it signed a three-year licensing agreement with AstraZeneca Plc. AZN to develop specialized ...

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

Holly has a degree in Medical Biochemistry from the University of Leicester. Her scientific interests include genomics, personalized medicine, and bioethics.View full profile Holly has a degree in ...